Head-to-head evidence
CPI-006 vs PT199
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: CD73 · full Non-Small Cell Lung Cancer pipeline
CPI-006
Developed by Corvus Pharmaceuticals and partners
NCT03454451 · Phase 1 · completed
Although the registry labels the allocation as randomized, none of the six groups received a placebo or an inactive comparator, and there was no blinding, so this functions as an open-label dose-escalation and combination study rather than a controlled comparison. The main goals were safety, tolerated dose, and drug levels. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
PT199
Developed by Phanes Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2027 · NCT05431270 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CPI-006's landscape · PT199's landscape